Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2015', provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Overview 6
Therapeutics Development 7
Pipeline Products for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview 7
Pipeline Products for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Comparative Analysis 8
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics under Development by Companies 9
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics under Investigation by Universities/Institutes 10
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Products under Development by Companies 13
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Products under Investigation by Universities/Institutes 14
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved in Therapeutics Development 15
CrystalGenomics, Inc. 15
Debiopharm International S.A. 16
iNtRON Biotechnology Inc. 17
Wockhardt Limited 18
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
CG-400549 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Debio-1450 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Epidermicin NI-01 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
S-0111340 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
S-0111342 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SAL-200 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SP-2078 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
WCK-4086 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Recent Pipeline Updates 40
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects 42
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables

Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H2 2015 7
Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics, Inc., H2 2015 15
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Debiopharm International S.A., H2 2015 16
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by iNtRON Biotechnology Inc., H2 2015 17
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Limited, H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 25
Number of Products by Stage and Molecule Type, H2 2015 27
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Therapeutics - Recent Pipeline Updates, H2 2015 40
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, H2 2015 42
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, H2 2015 43